Fidelity Disruptive Medicine ETF
FMED
NASDAQ Global Market- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management
- Address
- 245 Summer Street Boston MA United States of America 2210
- IPO Date
- Jun 12, 2023
- Website
- digital.fidelity.com
- Similar Companies
- Business
- Fidelity Disruptive Medicine ETF (FMED) is an actively managed exchange-traded fund that seeks long-term capital growth by investing at least 80% of its assets in equity securities of companies driving disruptive innovation in medicine and healthcare. The fund targets companies developing or providing innovative technologies, therapies, diagnostics, and services, including gene therapy, robotic surgery, digital health platforms, medical devices, biotechnology, pharmaceuticals, and health IT solutions; it employs fundamental analysis and quantitative portfolio construction to select growth and value stocks across domestic and foreign issuers, with a concentration in the healthcare sector. Top holdings as of late 2025 typically include Alnylam Pharmaceuticals Inc., Boston Scientific Corp., argenx SE, Danaher Corp., and Insulet Corp., among 65-71 total positions, with approximately 83% in U.S. equities and 17% in international developed and emerging market equities. FMED, issued by Fidelity Covington Trust, trades on the Nasdaq with ticker symbol FMED (CUSIP: 316092147), net expense ratio of 0.50%, and assets under management of approximately $55-56 million as of September 2025. The fund was incepted on April 16, 2020, and is headquartered in Boston, Massachusetts, at 245 Summer Street, the base for Fidelity Covington Trust, a Fidelity Investments affiliate. Recent developments include the addition of Edward Yoon as co-portfolio manager effective January 1, 2025, alongside existing managers Michael Kim and others, enhancing the team's expertise in healthcare equipment, supplies, and sector leadership; the fund has maintained its focus amid holdings involved in M&A activity, such as Icosavax's acquisition by AstraZeneca earlier in the period.